Activation of refractory T cell responses against hepatitis C virus core protein by ablation of interfering hydrophobic domains

被引:5
作者
Andersson, HA
Singh, RAK
Barry, MA
机构
[1] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
[2] Texas Childrens Hosp, Houston, TX 77030 USA
[3] Methodist Hosp, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA
[5] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[6] Rice Univ, Dept Bioengn, Houston, TX 77030 USA
关键词
HCV; core protein; hydrophobicity; ubiquitin; proteasome; genetic immunization; vaccine; cellular immunity;
D O I
10.1016/j.ymthe.2005.09.005
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Hepatitis C virus (HCV) is the major pathogen of chronic hepatitis and liver disease, but currently there are no prophylactic HCV vaccines available. The HCV core protein-encoding sequence is among the most conserved genes in the HCV genome, making it a prime candidate for a component of a vaccine. The core protein localizes to the endoplasmic reticulum (ER) through a C-terminal hydrophobic region that is cotranslationally inserted into the ER membrane. Here we show that removal of the C-terminal hydrophobic region confers nuclear localization and enhances proteasomal degradation of the core protein in mammalian cells. This efficient protein proteolysis induces enhanced core-specific CD8(+) T cell responses in BALB/c mice immunized with plasmids expressing C-terminal deletions of the HCV core protein. These results suggest that more potent HCV vaccines can be achieved by targeting the core protein for proteasomal degradation by deletion of its C-terminal hydrophobic domain.
引用
收藏
页码:338 / 346
页数:9
相关论文
共 52 条
[1]   Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].
Alter, HJ ;
Seeff, LB .
SEMINARS IN LIVER DISEASE, 2000, 20 (01) :17-35
[2]   Maximizing antigen targeting to the proteasome for gene-based vaccines [J].
Andersson, HA ;
Barry, MA .
MOLECULAR THERAPY, 2004, 10 (03) :432-446
[3]   Protein expression using ubiquitin fusion and cleavage [J].
Baker, RT .
CURRENT OPINION IN BIOTECHNOLOGY, 1996, 7 (05) :541-546
[4]   SEQUENCE-ANALYSIS OF THE CORE GENE OF 14 HEPATITIS-C VIRUS GENOTYPES [J].
BUKH, J ;
PURCELL, RH ;
MILLER, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (17) :8239-8243
[5]   ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME [J].
CHOO, QL ;
KUO, G ;
WEINER, AJ ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :359-362
[6]   GENETIC ORGANIZATION AND DIVERSITY OF THE HEPATITIS-C VIRUS [J].
CHOO, QL ;
RICHMAN, KH ;
HAN, JH ;
BERGER, K ;
LEE, C ;
DONG, C ;
GALLEGOS, C ;
COIT, D ;
MEDINASELBY, A ;
BARR, PJ ;
WEINER, AJ ;
BRADLEY, DW ;
KUO, G ;
HOUGHTON, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (06) :2451-2455
[7]  
Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO
[8]  
2-Q
[9]   Analysis of a successful immune response against hepatitis C virus [J].
Cooper, S ;
Erickson, AL ;
Adams, EJ ;
Kansopon, J ;
Weiner, AJ ;
Chien, DY ;
Houghton, M ;
Parham, P ;
Walker, CM .
IMMUNITY, 1999, 10 (04) :439-449
[10]   Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells [J].
Dantuma, NP ;
Lindsten, K ;
Glas, R ;
Jellne, M ;
Masucci, MG .
NATURE BIOTECHNOLOGY, 2000, 18 (05) :538-543